Zusammenfassung

• Objekte (1 geändert, 0 hinzugefügt, 0 gelöscht)
  • Wikiderm.EntryClass[0]

Details

Wikiderm.EntryClass[0]

Eintrag

...	...	@@ -79,14 +79,11 @@
79	79	(% class="Ebene-1" %)
80	80	(% class="Bullet" %)-(%%) Pemphigus foliaceus
81	81
82		-(% class="Ebene-1" %)
83		-(% class="Bullet" %)-(%%) anuläre Psoriasis pustulosa
	82	+(% class="Eintrag-2" %)
84	84
85		-(% class="Ebene-2" %)
86		-(% class="Feature" %)Bsp:(%%) annular pustular psoriasis
87	87
88		-(% class="Ebene-2" %)
89		-(% class="Feature" %)Lit:(%%) Pediatr Dermatol. 2023 Jan 31. [[http:~~/~~/doi.org/10.1111/pde.15251>>url:http://doi.org/10.1111/pde.15251]]
	85	+(% class="Ebene-1" %)
	86	+(% class="Bullet" %)-(%%) Psoriasis pustulosa
90	90
91	91	(% class="Ebene-1" %)
92	92	(% class="Bullet" %)-(%%) Tinea incognito
...	...	@@ -106,9 +106,6 @@
106	106	(% class="Ebene-1" %)
107	107	(% class="Bullet" %)-(%%) SAGE Open Med Case Rep. 2019 Jan 30;7:2050313X19826432. [[http:~~/~~/doi.org/10.1177/2050313X19826432>>url:http://doi.org/10.1177/2050313X19826432]]
108	108
109		-(% class="Ebene-1" %)
110		-(% class="Bullet" %)-(%%) JAAD Case Rep. 2022 Jan 21;21:185-188. [[http:~~/~~/doi.org/10.1016/j.jdcr.2021.04.039>>url:http://doi.org/10.1016/j.jdcr.2021.04.039]]
111		-
112	112	(% class="Eintrag-2" %)
113	113	(% class="Feature" %)Th:(%%) (% class="Bullet" %)-(%%) lokal
114	114
...	...	@@ -116,12 +116,6 @@
116	116	(% class="Bullet" %)-(%%) Farbstoffe (**[[Antiseptika]]**)
117	117
118	118	(% class="Ebene-2" %)
119		-(% class="Bullet" %)-(%%) Mometasonfuroat
120		-
121		-(% class="Ebene-3" %)
122		-(% class="Feature" %)Lit:(%%) Dermatol Ther. 2021 Nov 27:e15235. [[http:~~/~~/doi.org/10.1111/dth.15235>>url:http://doi.org/10.1111/dth.15235]]
123		-
124		-(% class="Ebene-2" %)
125	125	(% class="Bullet" %)-(%%) Tacalcitol
126	126
127	127	(% class="Ebene-3" %)
...	...	@@ -200,8 +200,14 @@
200	200	(% class="Feature" %)Stoff:(%%) (% class="Bullet" %)-(%%) **[[Infliximab]]**
201	201
202	202	(% class="Ebene-4" %)
203		-(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4, Dermatol Ther. 2022 May 4:e15552. [[http:~~/~~/doi.org/10.1111/dth.15552>>url:http://doi.org/10.1111/dth.15552]]
	191	+(% class="Feature" %)Phar:(%%) Remicade^^®^^
204	204
	193	+(% class="Ebene-4" %)
	194	+(% class="Feature" %)Dos:(%%) 5 mg/kg i.v.
	195	+
	196	+(% class="Ebene-4" %)
	197	+(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4
	198	+
205	205	(% class="Ebene-3" %)
206	206	(% class="Bullet" %)-(%%) Adalimumab
207	207
...	...	@@ -216,4 +216,3 @@
216	216
217	217	(% class="Ebene-3" %)
218	218	(% class="Feature" %)Lit:(%%) Int J Dermatol. 2021 Apr;60(4):e153-e154. [[http:~~/~~/doi.org/10.1111/ijd.15311>>url:http://doi.org/10.1111/ijd.15311]]
219		-